The purpose of the study is to see how safe and effective and tolerable the use of WelChol® is for type 2 diabetes when added to insulin alone or in combination with other anti-diabetic drugs
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
260
- To assess the additional lowering of HbA1c achieved by
addition of WelChol® to current antidiabetic therapy
To assess: the effects on fasting plasma glucose and
fructosamine; glycemic control response rate; effect on adiponectin; the effect on c-peptide; effect on c-reactive protein; effects on lipids and lipoproteins; the safety and tolerability of WelChol® as add-
on therapy to patients receiving insulin alone or with
other oral drugs
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Tuscumbia, Alabama, United States
Unnamed facility
Sierra Vista, Arizona, United States
Unnamed facility
Jonesboro, Arkansas, United States
Unnamed facility
Searcy, Arkansas, United States
Unnamed facility
Carmichael, California, United States
Unnamed facility
Concord, California, United States
Unnamed facility
Fullerton, California, United States
Unnamed facility
La Jolla, California, United States
Unnamed facility
San Diego, California, United States
Unnamed facility
West Hills, California, United States
...and 37 more locations